# Retatrutide cuts weight in a phase 3 trial

> In an 80-week randomized trial of adults with obesity but no diabetes, weekly retatrutide produced larger weight loss than placebo and improved knee pain and sleep-apnea events in prespecified subgroups; gastrointestinal adverse events were common, and long-term use remains an open question.

_Source: Peer-reviewed phase 3 NEJM trial; independently checked against PubMed, Europe PMC, Crossref and ClinicalTrials.gov · 2026-10-15 · 7 min read · Verified against primary sources_

Canonical: https://iyu.app/e/retatrutide-triumph-1-obesity-trial

## The 60-second version

In a phase 3 trial, weekly retatrutide produced substantially more average weight loss than placebo over 80 weeks, with additional subgroup improvements in knee pain and sleep-apnea events.

**Key points**

- 2,339 adults with obesity but no diabetes received 4, 9 or 12 mg retatrutide, or placebo.
- Mean weight change was −23.7% at 9 mg and −25.0% at 12 mg, versus −3.9% with placebo.
- Participants with knee osteoarthritis or obstructive sleep apnea also improved on prespecified outcomes.
- Gastrointestinal adverse events were the most common; the trial was funded by Eli Lilly.
- Long-term safety, weight maintenance after stopping and real-world access remain unanswered.

**Verdict.** This is strong evidence of 80-week weight reduction, not proof of a universal or lifelong treatment plan.

## Full explainer

> **i** This is a peer-reviewed phase 3 randomized, double-blind, placebo-controlled trial. It was funded by Eli Lilly, the developer of retatrutide, and the abstract reports gastrointestinal adverse events as the most common. Independent follow-up still matters.


### The trial — A once-weekly injection was tested for 80 weeks

TRIUMPH-1 assigned 2,339 adults with obesity and no diabetes to weekly retatrutide at 4, 9 or 12 milligrams, or to placebo. The trial was randomized and double-blind, so neither participants nor investigators knew the assigned treatment during the main comparison.

- **2,339** — adults randomized
- **80** — weeks of treatment
- **3** — retatrutide doses tested


### Weight — The largest doses produced the largest average losses

At week 80, mean body-weight change was minus 17.6% with 4 mg, minus 23.7% with 9 mg and minus 25.0% with 12 mg. The placebo group changed by minus 3.9%. The headline numbers are averages across groups, not individual guarantees.

- **Retatrutide 4 mg:** −17.6% mean weight change at week 80
- **Retatrutide 9 mg:** −23.7%; 19.8 percentage points beyond placebo
- **Retatrutide 12 mg:** −25.0%; 21.0 percentage points beyond placebo
- **Placebo:** −3.9% mean weight change


### Related conditions — Knee pain and sleep-apnea events also improved in subgroups

The study prespecified two relevant subgroups. Among 574 participants with knee osteoarthritis, WOMAC pain scores improved more with 9 or 12 mg than with placebo. Among 243 participants with obstructive sleep apnea, apnea-hypopnea events per hour fell more with retatrutide. These are meaningful signals, but they remain subgroup results from one trial.

- **Knee osteoarthritis:** 574 participants; 9 and 12 mg improved WOMAC pain more than placebo
- **Obstructive sleep apnea:** 243 participants; 9 and 12 mg reduced apnea-hypopnea events more than placebo


### Safety — The common downside was gastrointestinal

Gastrointestinal adverse events were the most common in the abstract. A short report cannot replace the full safety tables, and an 80-week trial cannot answer every question about multi-year use, discontinuation or weight regain after stopping.

> **⚑ Caveat:** The trial was funded by Eli Lilly, and several authors were affiliated with the company. That context does not erase the randomized design, but independent replication, longer follow-up and real-world evidence remain important.


### What it means — Strong evidence for weight reduction, not a finished treatment plan

- **What is supported:** retatrutide caused larger average weight reductions than placebo over 80 weeks in adults with obesity without diabetes.
- **What is promising:** the trial also found better knee-pain and sleep-apnea outcomes in prespecified subgroups.
- **What remains open:** long-term safety, weight maintenance after stopping, generalizability and access.
- **What to do:** treatment decisions should follow a clinician's assessment, not a percentage copied from a headline.

> The result is large, but the honest claim is narrow: this trial shows substantial average weight loss over 80 weeks.


## Primary sources

- [Telegram lead post 1554](https://t.me/CNSmydream/1554)
- [New England Journal of Medicine paper](https://doi.org/10.1056/NEJMoa2604169)
- [PubMed record and abstract](https://pubmed.ncbi.nlm.nih.gov/42814954/)
- [Europe PMC record and abstract](https://europepmc.org/article/MED/42814954)
- [ClinicalTrials.gov TRIUMPH-1 registration](https://clinicaltrials.gov/study/NCT05929066)
- [Crossref DOI metadata](https://api.crossref.org/works/10.1056/NEJMoa2604169)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._